Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

Learning to invest in doctors’ education

Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for...

M3 (EU)

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

Janssen shares new clinical trial data on its psoriasis treatment Tremfya

The results were presented at the 2022 AAD Annual Meeting in March

- PMLiVE

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older

- PMLiVE

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

There are an estimated 130,000 people with MS in the UK

Top 10 Tips for Running a Successful Virtual Event

As I explored in a recent article previously published on Pharmaphorum, the ways that pharmaceutical and scientific communities attend meetings and events completely changed in 2020. Virtual events are rapidly improving, as...

Impetus Digital

Removing Barriers to Pharmaceutical Accessibility & Affordability Worldwide

Dr. Dhiren Thakker, Founding President and CEO at Med Aditus, shares his insights into how blockchain and other leading-edge technologies can help revolutionize pharmaceutical manufacturing in sub-Saharan Africa and globally....

Impetus Digital

- PMLiVE

The Eleven guide to NFTs

Non-Fungible Tokens (NFTs) have been making waves in the news lately, specifically around the millions of dollars being exchanged for unique digital art assets. Investors have been queuing up to...

11 London

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

Pfizer receives Breakthrough Therapy Designation from FDA for RSV vaccine candidate

There are currently no preventative, therapeutic or vaccine options for older adults diagnosed with RSV

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Lucid Group Communications Limited

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links